Roxan Ara Selected Research

Glioblastoma (Glioblastoma Multiforme)

1/2021	Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
1/2019	Corrigendum to "CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma" Neoplasia, October 2018, Volume 20, Issue 10, Pages 1070-1082.
10/2018	CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
9/2017	Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.
1/2017	Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models.
1/2016	Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.
1/2016	Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roxan Ara Research Topics

Disease

13	Neoplasms (Cancer) 01/2021 - 12/2015
7	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 01/2016
3	Neoplasm Metastasis (Metastasis) 10/2019 - 01/2017
3	Hypoxia (Hypoxemia) 01/2016 - 12/2015
2	Bone Diseases (Bone Disease) 01/2021 - 08/2020
2	Glioma (Gliomas) 01/2021 - 10/2018
2	Breast Neoplasms (Breast Cancer) 01/2017 - 01/2017
1	Stroke (Strokes) 06/2021
1	Bone Resorption 08/2020
1	Disease Progression 10/2019
1	Inflammation (Inflammations) 01/2017

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2016
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2018 - 12/2015
3	CytokinesIBA 08/2020 - 01/2017
3	vatalanib (PTK787)IBA 10/2018 - 01/2016
3	HET0016IBA 09/2017 - 01/2017
2	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 09/2017 - 01/2017
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2017 - 01/2017
1	Radioisotopes (Radionuclides)IBA 10/2019
1	Bevacizumab (Avastin)FDA Link 10/2018
1	Interleukin-8 (Interleukin 8)IBA 10/2018
1	EndoglinIBA 10/2017
1	ChemokinesIBA 10/2017
1	Periodic AcidIBA 09/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Laminin (Merosin)IBA 01/2017
1	Metalloproteases (Metalloproteinases)IBA 01/2017
1	ChromatinIBA 01/2016
1	Therapeutic UsesIBA 01/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016
1	5- (3- methoxy- 4- ((4- methoxybenzyl)oxy)benzyl)pyrimidine- 2,4- diamineIBA 12/2015

Therapy/Procedure

9	Therapeutics 01/2021 - 12/2015
1	Intravenous Administration 06/2021
1	Immunomodulation 01/2021
1	Immunotherapy 01/2021
1	Aftercare (After-Treatment) 01/2016